Kidney Res Clin Pract.  2024 Nov;43(6):709-723. 10.23876/j.krcp.23.227.

Precision medicine for focal segmental glomerulosclerosis

• Xie Y
• Liu F

• KMID: 2564680
• DOI: http://doi.org/10.23876/j.krcp.23.227

Abstract

Focal segmental glomerulosclerosis (FSGS) is one of the common causes of nephrotic syndrome in adults and children worldwide. FSGS consists of a group of kidney diseases classified based on specific histopathological features. The current classification of FSGS makes it difficult to distinguish individual differences in pathogenesis, disease progression, and response to treatment. In recent years, the spread of next-generation sequencing, updates in biological techniques, and improvements of treatment have changed our understanding of FSGS. In this review, we will discuss the use of genetic testing in patients with FSGS, explore its clinical significance from a genetic identification perspective, and introduce several new biomarkers, that may help in the early diagnosis of FSGS and guide the development of specific or targeted therapies, so as to understand the biological characteristics in FSGS. This will certainly help develop more effective and safer treatments and advance precision medicine.

Keyword

Biomarkers; Focal segmental glomerulosclerosis; Genomics; Podocytes; Treatment